4
Changes in Ownership
Monopar Therapeutics Filed Acc 0001437749-26-031411
Chief Executive Officer sold 29,056 shares at an average $88.00 ($2,556,851)
- Chief Executive Officer acquired 29,056 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Robinson Chandler · Chief Executive Officer
Table I: Non-derivative
6 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-09-24 | Exercise or conversion : show line 1 in the form 10b5-1 | +14,056 | $30.00 | $421,680 | 113,323 | D |
| 2026-09-24 | Exercise or conversion : show line 2 in the form 10b5-1 | +15,000 | $14.00 | $210,000 | 128,323 | D |
| 2026-09-24 | Sale : show line 3 in the form 10b5-1 | −10,450 | $87.15 | $910,718 | 117,873 | D |
| 2026-09-24 | Sale : show line 4 in the form 10b5-1 | −9,638 | $87.96 | $847,758 | 108,235 | D |
| 2026-09-24 | Sale : show line 5 in the form 10b5-1 | −8,368 | $88.97 | $744,501 | 99,867 | D |
| 2026-09-24 | Sale : show line 6 in the form 10b5-1 | −600 | $89.79 | $53,874 | 99,267 | D |
| Open-market sales · 29,056 sh · avg $88.00 · $2,556,851 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-09-24 | Exercise or conversion : show line 7 in the form 10b5-1 Stock Option | −14,056 | 15,044 | D |
| 2026-09-24 | Exercise or conversion : show line 8 in the form 10b5-1 Stock Option | −15,000 | 27,204 | D |
Loading xslF345X06/rdgdoc.xml…